SOHO 2026 OPTIC 5-Year Update supports ponatinib dose optimization in CML, presented at a medical conference.
Leukemia / SOHO 10/21/2026

SOHO 2026: OPTIC 5-Year Update Supports Ponatinib Dose Optimization in CML

Key Points

  • At the Fourteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2026), the 5-year update from the phase 2 OPTIC trial showed a median event-free survival (EFS) of 57.2 months with a 45-mg starting dose of ponatinib compared with 30.6 months with 30 mg and 20.6 months with 15 mg.
  • In patients with a baseline BCR::ABL1 T315I mutation, median EFS was 55.2 months with 45 mg vs 13.3 and 13 months with the lower starting doses.
  • Response-based de-escalation to 15 mg preserved durable responses while lowering arterial occlusive event (AOE) rates over time.

At SOHO 2026, investigators presented the 5-year efficacy and safety update from the phase 2 OPTIC trial (NCT02467270), which evaluated dose optimization of ponatinib, a third-generation tyrosine kinase inhibitor (TKI), in chronic myeloid leukemia (CML).1 Previous findings from the phase 2 PACE trial demonstrated ponatinib’s efficacy but also highlighted notable toxicities, including hypertension, pancreatitis, AOEs, and rash.2 The OPTIC update focused on 5-year EFS and long-term safety.

The Rationale and Objectives of the OPTIC Trial

PACE established ponatinib at 45 mg daily as an effective option for heavily pretreated chronic phase (CP)-CML, including patients with the gatekeeper T315I mutation.2 Individuals with T315I mutation have resistance to imatinib and the second-generation TKIs. With longer follow-up, AOEs emerged as a defining toxicity, reaching a cumulative incidence of roughly 31% at 5 years in PACE.2 Pooled analyses then suggested a dose-dependent relationship between ponatinib exposure and AOEs.3-4

OPTIC was designed to test a straightforward hypothesis: induce response at a higher dose, then de-escalate to maintain it.5

OPTIC Study Design

  • Population: 283 adults with CP-CML resistant or intolerant to ≥2 prior TKIs, or with a T315I mutation, enrolled at 61 sites in 19 countries
  • Randomization: 1:1:1 to ponatinib starting doses of 45 mg, 30 mg, or 15 mg once daily
  • Response-based de-escalation: In the 45-mg and 30-mg cohorts, dose was reduced to 15 mg upon achieving ≤1% BCR::ABL1IS; reductions to 10 mg were permitted for adverse events (AEs)
  • Re-escalation: Allowed back to the starting dose after confirmed loss of ≤1% BCR::ABL1IS on two consecutive assessments
  • Primary end point: ≤1% BCR::ABL1IS at 12 months

Nearly all patients (99%) had TKI-resistant disease. There were 55% who had received three or more prior TKIs and 24% had a T315I mutation at baseline. Another 17% had non-T315I mutations, and 58% had no detectable BCR::ABL1 mutation. At the 5-year data cutoff, median follow-up was 75 months to 78 months across cohorts.

Key Findings: Molecular Response

At 5 years, ≤1% BCR::ABL1IS was achieved by 60% of patients in the 45-mg cohort, 41% in the 30-mg cohort, and 40% in the 15-mg cohort. Most responses occurred within the first 2 years, and no new responses emerged after year 4. Median time to response was 6 months in the 45-mg cohort, 3.1 months in the 30-mg cohort, and 6.2 months in the 15-mg cohort.5

Deeper responses correlated with the higher 45 mg starting dose. Major molecular response (MMR; ≤0.1% BCR::ABL1IS) by 5 years was 46% with 45 mg compared with 29% with 30 mg and 24% with 15 mg. Rates of MR4 and MR4.5 were similar across cohorts.5 The starting-dose effect was most pronounced in patients with T315I. In this subgroup, ≤1% BCR::ABL1IS by 5 years was reached in 64% with 45 mg versus 25% with 30 mg and 16% with 15 mg. In patients with non-T315I mutations or no mutations, response rates were only modestly higher in the 45-mg cohort.5

Durability of Disease Control

The OPTIC study showed that if a response is achieved, it tends to last even after dose reduction. 

  • Response maintenance: Median duration of ≤1% BCR::ABL1IS was not reached in any cohort. By Kaplan-Meier estimation, the proportion maintaining response at 5 years was 68.8% in the 45-mg cohort, 74.4% in the 30-mg cohort, and 84.3% in the 15-mg cohort. 
  • De-escalation works: Protocol-mandated reduction to 15 mg after response occurred in 80% of responders in the 45-mg cohort and 71% in the 30-mg cohort. Response was maintained after reduction in 69% and 78% of these patients, respectively.
  • Re-escalation rescues most losses: Among patients who lost response and had their dose re-escalated, 69% in the 45-mg cohort and 80% in the 30-mg cohort regained ≤1% BCR::ABL1IS.
  • Long-term treatment exposure: Of 282 treated patients, 30% remained on ponatinib for 5 years or longer (range, 60–105 months). At data cutoff, 29% of the 45-mg cohort remained on treatment versus 19% and 17% of the 30-mg and 15-mg cohorts.

In addition, in the published analysis, stopping for lack of efficacy was more common with lower starting doses (30% with 15 mg and 23% with 30 mg vs 17% with 45 mg). In the SOHO update, discontinuation because of AEs was similar across arms: 21.3% with 45 mg, 18.9% with 30 mg, and 18.1% with 15 mg (19.4% overall). In other words, starting low did not buy meaningfully better tolerability over time, but it did cause lower efficacy.

5-Year EFS Update From OPTIC

The headline data from SOHO 2026 were the 5-year EFS results, which Michael W. Deininger, MD, of University of Michigan Health, presented across all three dosing arms. 

Median EFS at 5 years:

Population45 mg → 15 mg30 mg → 15 mg15 mg
All patients57.2 months30.6 months20.6 months
Baseline T315I55.2 months13.3 months13.0 months

The 45 mg starting dose nearly doubled median EFS compared with 30 mg and nearly tripled it compared with 15 mg.1 In T315I-mutated disease, the difference was even more pronounced. Patients who started at 45 mg remained event-free for a median of more than 4.5 years, whereas those starting at 30mg had an event-free median of 13.3 months. 

Progression-Free Survival and Overall Survival

Overall population5:

Outcome45 mg → 15 mg30 mg → 15 mg15 mg
5-year Progression-Free Survival (PFS)63%57%60%
Median PFSNot reached75.0 monthsNot reached
5-year Overall Survival (OS)85.1%83.3%86.4%
Progression to AP-CML on study12%12%14%

5-year PFS and OS by baseline mutation status5:

Subgroup45 mg → 15 mg30 mg → 15 mg15 mg
T315I: PFS58%25%31%
T315I: OS86%62%69%
Non-T315I mutation: PFS40%61%57%
Non-T315I mutation: OS80%92%82%
No mutation: PFS72%69%74%
No mutation: OS86%90%94%

Two observations stand out. First, for patients with T315I, the 45 mg starting dose was associated with superior event-free and overall outcomes, with median PFS not reached. The median PFS was 28.4 months in the 30-mg cohort and 21 months in the 15-mg cohort. A 5-year OS of 86% was seen in the heavily pretreated T315I-positive CP-CML. 

Long-Term Safety: The Arterial Signal Declines

Adjudicated treatment-emergent AOEs occurred in 13.8%, 9.6%, and 5.3% of patients in the 45-mg, 30-mg, and 15-mg cohorts, respectively. Exposure-adjusted rates were 4.1, 3.8, and 2 events per 100 patient-years, respectively. The AOEs were roughly half the rate reported in PACE (8.9 per 100 patient-years). Importantly, AOE incidence in the 45-mg cohort trended downward over time, remaining at 3% or less per year after year 2, which is consistent with lower cumulative exposure after de-escalation.

However, the PACE population was older, and cardiovascular risk management has overall improved since that trial. Still, the trend supports the biological logic of de-escalation. Two fatal AOEs occurred, both in the 45-mg cohort. Venous thromboembolic events were rare (1%).

Other toxicities were familiar. The most common nonhematologic AE was hypertension (35% overall; grade 3/4 in 10%), followed by headache and alanine aminotransferase elevation. Thrombocytopenia was the most common hematologic event (40%; grade 3/4 in 27%).

Mutational Control at End of Treatment

Among 64 patients with baseline mutations, 18 had those mutations reduced below the limit of detection. Among 83 evaluable patients who discontinued for lack of efficacy or progression, 86.7% acquired no new detectable mutations. Of the 11 who did, 6 had T315I together with an additional mutation at end of treatment, a pattern that may reflect compound mutations, against which ponatinib has reduced preclinical activity.

Clinical Perspective

For patients with T315I-positive CP-CML, starting ponatinib at 45 mg and reducing the dose to 15 mg after achieving a BCR::ABL1 level of ≤1% on the International Scale yielded the most favorable overall outcomes. The benefits in response, PFS, and OS were among the most consistent findings in this subgroup. Most patients who responded maintained their response after dose reduction, and most who lost response regained it after dose re-escalation, highlighting the importance of close molecular monitoring. Aggressive cardiovascular risk management, including blood pressure, lipid, and diabetes control and smoking cessation, also remains essential.

Comparisons with asciminib remain indirect, as no head-to-head randomized data are available in the third-line setting. Treatment selection should account for the patient’s mutation profile, comorbidities, and access to therapy. 

These findings should also be interpreted in the context of the study’s limitations: OPTIC was an open-label, industry-sponsored phase 2 trial that was not powered for formal comparisons between dose cohorts, and several mutation subgroups were small.

References

  1. Deininger MW, et al. Event-free survival and safety with ponatinib in patients with chronic-phase chronic myeloid leukemia: 5-year follow-up of OPTIC. Presented at: Fourteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2026); September 9-12, 2026; Houston, TX.
  2. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393-404. doi:10.1182/blood-2016-09-739086
  3. Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138(21):2042-2050. doi:10.1182/blood.2021012082
  4. Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612-621. doi:10.1016/S1470-2045(16)00080-2
  5. Kantarjian H, Deininger M., Apperley JF, et al. Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. Leukemia. 2026;40:1882–1892. doi:10.1038/s41375-026-03009-x